Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SZSE:002693'
s Net Margin % Range Over the Past 10 Years
Min: -267.62 Med: -13.07 Max: 16.51
Current: 16.51
SZSE:002693's Net Margin % is ranked better than 82.93% of 961
companies
in the Drug Manufacturers industry
Industry Median: 5.18
vs SZSE:002693: 16.51
Hainan Shuangcheng Pharmaceuticals Co (SZSE:002693) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Hainan Shuangcheng Pharmaceuticals Co Net Margin % Related Terms
Hainan Shuangcheng Pharmaceuticals Co Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hainan Shuangcheng Pharmaceuticals Co Net Margin % Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Hainan Shuangcheng Pharmaceuticals Co's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hainan Shuangcheng Pharmaceuticals Co Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hainan Shuangcheng Pharmaceuticals Co's Net Margin % distribution charts can be found below:
* The bar in red indicates where Hainan Shuangcheng Pharmaceuticals Co's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hainan Shuangcheng Pharmaceuticals Co (SZSE:002693) has a Net Margin % of 14.81% as of Jun. 2026. Net margin is the ratio of total net income to net sales. View historical data on Hainan Shuangcheng Pharmaceuticals Co and its competitors. According to the industry distribution chart, Hainan Shuangcheng Pharmaceuticals Co ranks #164 out of 961 companies in the Drug Manufacturers industry, placing it in the top 17.1%.
Is Hainan Shuangcheng Pharmaceuticals Co's Net Margin % too high?
Hainan Shuangcheng Pharmaceuticals Co's current Net Margin % is 14.81%. The Drug Manufacturers industry median Net Margin % is 5.18. Hainan Shuangcheng Pharmaceuticals Co's value of 14.81% is 185.9% above this industry median. Based on the distribution chart, Hainan Shuangcheng Pharmaceuticals Co ranks #164 out of 961 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Hainan Shuangcheng Pharmaceuticals Co has a GF Score™ of 55/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Hainan Shuangcheng Pharmaceuticals Co's Net Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Hainan Shuangcheng Pharmaceuticals Co ranks #164 out of 961 companies for Net Margin %. This places Hainan Shuangcheng Pharmaceuticals Co in the top 17% of its industry — outperforming the majority of peers. The industry median Net Margin % is 5.18. Hainan Shuangcheng Pharmaceuticals Co's value of 14.81% is 185.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.18, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hainan Shuangcheng Pharmaceuticals Co's current Net Margin % of 14.81% is 185.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Hainan Shuangcheng Pharmaceuticals Co and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.18 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hainan Shuangcheng Pharmaceuticals Co's current Net Margin % is 14.81%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hainan Shuangcheng Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Hainan Shuangcheng Pharmaceuticals Co (SZSE:002693) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥11.57, compared to a current price of ¥8.75 — trading 24.4% below its estimated fair value. The current Net Margin % is 14.81% and 185.9% above the Drug Manufacturers industry median of 5.18. Hainan Shuangcheng Pharmaceuticals Co's overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Hainan Shuangcheng Pharmaceuticals Co (SZSE:002693), the current Net Margin % is 14.81% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hainan Shuangcheng Pharmaceuticals Co (SZSE:002693) Overvalued in 2026?
Based on GuruFocus' analysis, Hainan Shuangcheng Pharmaceuticals Co stock appears to be undervalued.
The current stock price of ¥8.75 is trading 24.4% below its estimated GF Value™ of ¥11.57.
GuruFocus considers Hainan Shuangcheng Pharmaceuticals Co to be Modestly Undervalued.
Key valuation signals for SZSE:002693:
Net Margin %: 14.81%
GF Value™: ¥11.57 vs. price of ¥8.75 (24.4% below fair value)
Industry Position: 185.9% above the Drug Manufacturers median (#164 of 961)
No single metric tells the full story. See the SZSE:002693 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SZSE:002693 has been successfully added to your 
